Analysts Set Inovio Pharmaceuticals, Inc. (NASDAQ:INO) PT at $9.00

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has been given a consensus rating of “Hold” by the nine ratings firms that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $9.00.

Several equities analysts have recently commented on the company. Piper Sandler restated an “overweight” rating and issued a $6.00 price objective (up from $5.00) on shares of Inovio Pharmaceuticals in a research report on Friday, November 14th. HC Wainwright reissued a “neutral” rating on shares of Inovio Pharmaceuticals in a research note on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Inovio Pharmaceuticals in a report on Monday. Citigroup reaffirmed a “market outperform” rating on shares of Inovio Pharmaceuticals in a report on Tuesday, November 4th. Finally, UBS Group reiterated an “overweight” rating on shares of Inovio Pharmaceuticals in a research report on Friday, November 14th.

Inovio Pharmaceuticals Price Performance

Shares of NASDAQ INO opened at $1.69 on Wednesday. The firm has a fifty day moving average price of $2.10 and a 200-day moving average price of $2.05. The stock has a market cap of $112.77 million, a PE ratio of -0.65 and a beta of 1.62. Inovio Pharmaceuticals has a 1 year low of $1.30 and a 1 year high of $2.98.

Inovio Pharmaceuticals (NASDAQ:INO) last released its earnings results on Monday, November 10th. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.07. On average, research analysts expect that Inovio Pharmaceuticals will post -4.23 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in INO. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Inovio Pharmaceuticals by 39.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company’s stock worth $34,000 after buying an additional 5,894 shares in the last quarter. Bank of Montreal Can raised its holdings in shares of Inovio Pharmaceuticals by 23.7% during the 2nd quarter. Bank of Montreal Can now owns 57,946 shares of the biopharmaceutical company’s stock worth $118,000 after acquiring an additional 11,110 shares in the last quarter. MCF Advisors LLC purchased a new stake in shares of Inovio Pharmaceuticals during the 3rd quarter worth approximately $26,000. SG Americas Securities LLC bought a new position in shares of Inovio Pharmaceuticals during the 3rd quarter valued at approximately $27,000. Finally, Stephens Inc. AR purchased a new position in shares of Inovio Pharmaceuticals in the third quarter valued at $32,000. Hedge funds and other institutional investors own 26.79% of the company’s stock.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.